Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangqin Gel is a botanical drug product developed by Shandong Hanfang Pharmaceutical for the treatment of vulvovaginal candidiasis (VVC). It is specifically indicated for patients presenting with the "damp-heat downward flow" pattern according to Traditional Chinese Medicine (TCM) principles. The primary active component is derived from *Scutellaria baicalensis* (Huangqin), which contains bioactive flavonoids such as baicalin and baicalein known for their anti-inflammatory and antimicrobial properties. The drug is currently being evaluated in Phase 2 clinical trials (e.g., CTR20260702) to assess its efficacy and safety in women with uncomplicated VVC.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huangqin Gel.